Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations

Summary

This is Phase IV, Open label, Multicenter study. Subject's parents and/or legal guardian will be provided information about the trial. If interested and if eligible, they will then be asked to provide signed informed consent. The initial study visit can occur immediately after signed informed consent has been obtained. Approximately 135 subjects will be enrolled to receive 4 doses of intramuscular MenACWY vaccine at 2, 4, 6 and 12 months of age.

Timeline

Start

2015-07-13

Primary completion

2017-12-28

Completion

2017-12-28

Drugs

Indications